RIGL vs. INOD

Last updated Jun 13, 2026

RIGL (Rigel Pharmaceuticals, Inc.) and INOD (Innodata Inc.) are both stocks. RIGL operates in Biotechnology (Healthcare), while INOD operates in Information Technology Services (Technology). Over the past 10 years, RIGL returned 3.28%/yr vs 45.64%/yr for INOD. At a 0.11 correlation, their price movements are largely independent.

Performance

RIGL vs. INOD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rigel Pharmaceuticals, Inc. (RIGL) and Innodata Inc. (INOD). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, RIGL achieves a -23.30% return, which is significantly lower than INOD's 98.04% return. Over the past 10 years, RIGL has underperformed INOD with an annualized return of 3.28%, while INOD has yielded a comparatively higher 45.64% annualized return.

RIGL

• 1D: 2.40%
• 1M: 2.24%
• YTD: -23.30%
• 6M: -19.45%
• 1Y: 54.23%
• 3Y*: 27.10%
• 5Y*: -3.96%
• 10Y*: 3.28%

INOD

• 1D: -4.23%
• 1M: 12.17%
• YTD: 98.04%
• 6M: 92.56%
• 1Y: 137.86%
• 3Y*: 114.32%
• 5Y*: 69.37%
• 10Y*: 45.64%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RIGL vs. INOD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
RIGL Rigel Pharmaceuticals, Inc.	-23.30%	154.64%	16.00%	-3.33%	-43.40%	-24.29%	63.55%	-6.96%	-40.72%	63.03%
INOD Innodata Inc.	98.04%	28.92%	385.50%	174.54%	-49.92%	11.70%	364.91%	-24.00%	10.29%	-44.49%

Correlation

The correlation between RIGL and INOD is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (10Y) Calculated over the trailing 10-year period	0.15
Correlation (All Time) Calculated using the full available price history since Nov 29, 2000	0.11

The correlation between RIGL and INOD shifts across timeframes, from 0.07 (1 year) to 0.19 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap RIGL : $646.69M INOD : $3.59B
EPS RIGL : $19.21 INOD : $1.11
PE Ratio RIGL : 1.71 INOD : 90.91
PEG Ratio RIGL : 0.00 INOD : 0.02
PS Ratio RIGL : 2.08 INOD : 12.60
PB Ratio RIGL : 1.62 INOD : 28.00
Total Revenue (TTM) RIGL : $299.77M INOD : $283.42M
Gross Profit (TTM) RIGL : $279.95M INOD : $76.88M
EBITDA (TTM) RIGL : $125.80M INOD : $37.35M

Return for Risk

RIGL vs. INOD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RIGL

RIGL Risk / Return Rank: 67
RIGL Sharpe Ratio Rank: 68
RIGL Sortino Ratio Rank: 70
RIGL Omega Ratio Rank: 69
RIGL Calmar Ratio Rank: 65
RIGL Martin Ratio Rank: 61

INOD

INOD Risk / Return Rank: 79
INOD Sharpe Ratio Rank: 77
INOD Sortino Ratio Rank: 86
INOD Omega Ratio Rank: 83
INOD Calmar Ratio Rank: 78
INOD Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RIGL vs. INOD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and Innodata Inc. (INOD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	RIGL	INOD	Difference
Sharpe ratio: Return per unit of total volatility	0.78	1.14	-0.36
Sortino ratio: Return per unit of downside risk	1.64	2.64	-1.00
Omega ratio: Gain probability vs. loss probability	1.20	1.31	-0.11
Calmar ratio: Return relative to maximum drawdown	1.09	2.20	-1.11
Martin ratio: Return relative to average drawdown	1.91	3.97	-2.07

RIGL vs. INOD - Sharpe Ratio Comparison

The current RIGL Sharpe Ratio is 0.78, which is lower than the INOD Sharpe Ratio of 1.14. The chart below compares the historical Sharpe Ratios of RIGL and INOD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

RIGL vs. INOD - Drawdown Comparison

The maximum RIGL drawdown since its inception was -99.37%, roughly equal to the maximum INOD drawdown of -95.47%. Use the drawdown chart below to compare losses from any high point for RIGL and INOD.

Drawdown Indicators

	RIGL	INOD	Difference
Max Drawdown Largest peak-to-trough decline	-99.37%	-95.47%	-3.90%
Max Drawdown (1Y) Largest decline over 1 year	-50.08%	-63.03%	+12.95%
Max Drawdown (3Y) Largest decline over 3 years	-57.75%	-63.03%	+5.28%
Max Drawdown (5Y) Largest decline over 5 years	-85.24%	-74.44%	-10.80%
Max Drawdown (10Y) Largest decline over 10 years	-86.40%	-74.44%	-11.96%
Current Drawdown Current decline from peak	-96.93%	-16.95%	-79.98%
Average Drawdown Average peak-to-trough decline	-90.91%	-60.07%	-30.84%
Ulcer Index Depth and duration of drawdowns from previous peaks	28.64%	34.83%	-6.19%

Volatility

RIGL vs. INOD - Volatility Comparison

The current volatility for Rigel Pharmaceuticals, Inc. (RIGL) is 12.05%, while Innodata Inc. (INOD) has a volatility of 32.31%. This indicates that RIGL experiences smaller price fluctuations and is considered to be less risky than INOD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RIGL	INOD	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.05%	32.31%	-20.26%
Volatility (6M) Calculated over the trailing 6-month period	36.64%	89.40%	-52.76%
Volatility (1Y) Calculated over the trailing 1-year period	69.89%	122.08%	-52.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.46%	106.74%	-21.28%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	82.81%	89.36%	-6.55%

Dividends

RIGL vs. INOD - Dividend Comparison

Neither RIGL nor INOD has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

RIGL vs. INOD - Profitability Comparison

The chart below illustrates the profitability comparison between Rigel Pharmaceuticals, Inc. and Innodata Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RIGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.

INOD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Innodata Inc. reported a gross profit of 0.00 and revenue of 90.10M. Therefore, the gross margin over that period was 0.0%.

RIGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.

INOD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Innodata Inc. reported an operating income of 0.00 and revenue of 90.10M, resulting in an operating margin of 0.0%.

RIGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.

INOD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Innodata Inc. reported a net income of 14.90M and revenue of 90.10M, resulting in a net margin of 16.5%.

Frequently Asked Questions

Can I hold both RIGL and INOD in my portfolio?

RIGL and INOD have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, RIGL or INOD?

INOD has higher volatility (32.31%) compared to RIGL (12.05%). In terms of maximum drawdown, RIGL dropped -99.37% vs INOD's -95.47%.

Which has better risk-adjusted returns?

INOD currently has the higher Sharpe Ratio (1.14 vs 0.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.